Dunhill Financial’s Amicus Therapeutics FOLD Stock Holding History

Dunhill Financial’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$76	Hold	5	–	–	﹤0.01%	1500
2025 Q4	$76	Buy	+5	New	+$49	﹤0.01%	1495

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Dunhill Financial's FOLD Position: Q1 2026 in Review

Dunhill Financial held its Amicus Therapeutics (FOLD) position steady in Q1 2026 at 5 shares worth $76. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Dunhill Financial first reported a position in FOLD in Q4 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Dunhill Financial held 5 shares of Amicus Therapeutics worth $76 as of Q1 2026.
Dunhill Financial left its Amicus Therapeutics share count unchanged in Q1 2026.
Amicus Therapeutics made up ﹤0.01% of Dunhill Financial's portfolio in Q1 2026, its #1500 holding.
Dunhill Financial first reported a position in Amicus Therapeutics in Q4 2025 and has held it in 2 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Dunhill Financial's 13F filing for Q1 2026, filed 6 May 2026.